But wait – there’s more!
Join The True Defender Telegram Chanel Here: https://t.me/TheTrueDefender
According to the investigation, the Bill & Melinda Gates Foundation are also the primary funders of the UK’s Medicine & Healthcare products Regulatory Agency!
According to the official report published by The Daily Expose,
“The Medicine & Healthcare products Regulatory Agency (MHRA) extended the emergency authorization of the Pfizer / BioNTech mRNA jab in the UK to allow it to be given to children between the ages of 12 – 15 on the 4th June 2021.
At the time, the Chief Executive of the MHRA, Dr. June Raine said the MHRA had “carefully reviewed clinical trial data in children aged 12 to 15 years and have concluded that the Pfizer vaccine is safe and effective in this age group and that the benefits outweigh any risk”.
We are left wondering if Dr. June Raine and the MHRA have even read the results of the extremely short and small study. If they have then they would have seen that 86% of children in the study suffered an adverse reaction ranging from mild to extremely serious.
Just 1,127 children took part in the trial, however, only 1,097 children completed the trial, with 30 of them not participating after being given the first dose of the Pfizer jab. The results do not state why the 30 children did not go on to complete the trial.”
The Bill & Melinda Gates Foundation bought shares in Pfizer back in 2002, and back in September 2020 Bill Gates ensured the value of his shares went up by announcing to the mainstream media in a CNBC interview that he viewed Pfizer jab as the leader in the Covid-19 vaccine race.
“The only vaccine that, if everything went perfectly, might seek the emergency use license by the end of October, would be Pfizer.”
The Bill & Melinda Gates Foundation also “coincidentally” bought $55 million worth of shares in BioNTech in September 2019, just before the alleged Covid-19 pandemic struck.
NOTICE: The information is publicly available and contained within an FDA fact sheet which can be viewed here (see page 25, table 5 on-wards).